Opdivo (nivolumab) + Yervoy (ipilimumab) Drug Insight and Market Forecast - 2032

“Opdivo (nivolumab) + Yervoy (ipilimumab) Drug Insight and Market Forecast - 2032” report provides comprehensive insights about Opdivo (nivolumab) + Yervoy (ipilimumab) for Metastatic Colorectal Cancer in the 7MM. A detailed picture of the Opdivo (nivolumab) + Yervoy (ipilimumab) for Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Opdivo (nivolumab) + Yervoy (ipilimumab) for Metastatic Colorectal Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Opdivo (nivolumab) + Yervoy (ipilimumab) market forecast, analysis for Metastatic Colorectal Cancer in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Metastatic Colorectal Cancer.

Drug Summary

Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth. Combined nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) mediated inhibition results in an enhanced T-cell function that is greater than the effects of either antibody alone and results in improved anti-tumor responses in metastatic melanoma and advanced RCC. In murine syngeneic tumor models, dual blockade of PD-1 and CTLA-4 resulted in increased anti-tumor activity.

In July 2018, the Food and Drug Administration granted accelerated approval to ipilimumab for use in combination with nivolumab for the treatment of patients 12 years of age and older with MSI-H or dMMR mCRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Mechanism of Action

Nivolumab is a genetically engineered anti-PD-1 mAb, developed by immunizing transgenic mice for human immunoglobulin loci with recombinant Chinese hamster ovary cells expressing human PD-1 and PD-1/human IgG1 Fc fusion protein Nivolumab contains a hinge region mutation, the mutation reduces Fc exchange with serum IgG4 molecules to improve stability and reduce therapeutic variability. Nivolumab binds PD-1 with high affinity, blocks its interactions with both PD-L1 and PD-L2, and stimulates memory response to tumor antigen-specific T cell proliferation.

Mechanism of action of ipilimumab: Competitive inhibition of CD28-B7.1/B7.2 binding by CTLA-4 suppresses T cell activation and prevents an immune response. Blockade of CTLA-4 with ipilimumab allows continued T cell activation to augment the antitumor response.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Opdivo (nivolumab) + Yervoy (ipilimumab) description, mechanism of action, dosage and administration, research and development activities in Metastatic Colorectal Cancer.
• Elaborated details on Opdivo (nivolumab) + Yervoy (ipilimumab) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Opdivo (nivolumab) + Yervoy (ipilimumab) research and development activity in Metastatic Colorectal Cancer in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Opdivo (nivolumab) + Yervoy (ipilimumab).
• The report contains forecasted sales of Opdivo (nivolumab) + Yervoy (ipilimumab) for Metastatic Colorectal Cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Metastatic Colorectal Cancer.
• The report also features the SWOT analysis with analyst views for Opdivo (nivolumab) + Yervoy (ipilimumab) in Metastatic Colorectal Cancer.

 

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Opdivo (nivolumab) + Yervoy (ipilimumab) Analytical Perspective

In-depth Opdivo (nivolumab) + Yervoy (ipilimumab) Market Assessment

This report provides a detailed market assessment of Opdivo (nivolumab) + Yervoy (ipilimumab) in Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

Opdivo (nivolumab) + Yervoy (ipilimumab) Clinical Assessment

The report provides the clinical trials information of Opdivo (nivolumab) + Yervoy (ipilimumab) in Metastatic Colorectal Cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Metastatic Colorectal Cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Opdivo (nivolumab) + Yervoy (ipilimumab) dominance.
• Other emerging products for Metastatic Colorectal Cancer are expected to give tough market competition to Opdivo (nivolumab) + Yervoy (ipilimumab) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Opdivo (nivolumab) + Yervoy (ipilimumab) in Metastatic Colorectal Cancer.
• This in-depth analysis of the forecasted sales data of Opdivo (nivolumab) + Yervoy (ipilimumab) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Opdivo (nivolumab) + Yervoy (ipilimumab) in Metastatic Colorectal Cancer.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of Opdivo (nivolumab) + Yervoy (ipilimumab)?
• What is the clinical trial status of the study related to Opdivo (nivolumab) + Yervoy (ipilimumab) in Metastatic Colorectal Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Opdivo (nivolumab) + Yervoy (ipilimumab) development?
• What are the key designations that have been granted to Opdivo (nivolumab) + Yervoy (ipilimumab) for Metastatic Colorectal Cancer?
• What is the forecasted market scenario of Opdivo (nivolumab) + Yervoy (ipilimumab) for Metastatic Colorectal Cancer?
• What are the forecasted sales of Opdivo (nivolumab) + Yervoy (ipilimumab) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Metastatic Colorectal Cancer and how are they giving competition to Opdivo (nivolumab) + Yervoy (ipilimumab) for Metastatic Colorectal Cancer?
• Which are the late-stage emerging therapies under development for the treatment of Metastatic Colorectal Cancer?

This product will be delivered within 2 business days.